Meeting
2022 ASCO Annual Meeting
Five-year results of a phase 2 trial using ipilimumab (I), nivolumab (N), and trabectedin (T) for previously untreated advanced soft tissue sarcoma (NCT03138161).
Authors
Erlinda Maria Gordon
Sarcoma Oncology Research Center, Santa Monica, CA
Erlinda Maria Gordon , Sant P. Chawla , Victoria S. Chua-Alcala , Ted T. Kim , Noufil Adnan , Simranjit Sekhon , Nicole Angel , Mitchel Fernando , Don Arlen Brigham , Doris V. Quon , Ania Moradkhani , Steve Wong
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Sarcoma
Track
Sarcoma
Sub Track
Soft Tissue Tumors
Clinical Trial Registration Number
NCT03138161
Citation
J Clin Oncol 40, 2022 (suppl 16; abstr 11573)
DOI
10.1200/JCO.2022.40.16_suppl.11573
Abstract #
11573
Poster Bd #
477
Abstract Disclosures
Similar Posters
Poster
2020 ASCO Virtual Scientific Program
![SAINT: Results of an expanded phase II study using safe amounts of ipilimumab (I), nivolumab (N), and trabectedin (T) as first-line treatment of advanced soft tissue sarcoma [NCT03138161].](https://d201v5jt9ylckg.cloudfront.net/258/14787/186779/186779_poster_pv.jpg)
SAINT: Results of an expanded phase II study using safe amounts of ipilimumab (I), nivolumab (N), and trabectedin (T) as first-line treatment of advanced soft tissue sarcoma [NCT03138161].
First Author: Erlinda Maria Gordon
Poster
2019 ASCO-SITC Clinical Immuno-Oncology Symposium
The SAINT: Initial results of a phase I/II study of safety/efficacy using safe amounts of ipilimumab, nivolumab, and trabectedin as first-line treatment of advanced soft tissue sarcoma.
First Author: Sant P. Chawla
Poster
2019 ASCO Annual Meeting
SAINT: Results of a phase 1/2 study of safety/efficacy using safe amounts of ipilimumab, nivolumab, and trabectedin as first-line treatment of advanced soft tissue sarcoma.
First Author: Erlinda Maria Gordon
Poster
2024 ASCO Annual Meeting
Seven year update on SOC-1702: A phase 2 study using trabectedin (T) in combination with ipilimumab (I), nivolumab (N) and trabectedin (T) in previously untreated patients with advanced soft tissue sarcoma.
First Author: Erlinda Maria Gordon